Will Patients with Kidney Disease Eventually Receive New Drug Class?

Published Date: 21 Oct 2023

Just over 2 years ago, dapagliflozin became the first SGLT2 inhibitor to be authorized for CKD alone, but uptake has been slow. Could change be sparked by a similar label gain for empagliflozin and a fresh suggestion?

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot